Report
Description
Report Description
BLyS-specific Inhibitors or Monoclonal Antibodies (MAbS)
Belimumab (Benlysta)
Immunosuppressive Agents/Immune Modulators
Azathioprine (Imuran)
Methotrexate (Rheumatrex)
Cyclophosphamide (Cytoxan)
Anticoagulants
Low-dose aspirin
Heparin (Calciparine, Liquaemin)
Warfarin (Coumadin)
Systemic Lupus Erythematous (SLE) Drugs Market: Overview
Global systemic lupus erythematous drugs market growth is fast in North American region and is
estimated to project remarkable CAGR growth throughout forecast period. In North America,
the SLE is more prevalent among Hispanics, Asians, and Native Americans according to Centers
for Disease Control and Prevention (CDC). The second largest and fastest growing global
systemic lupus erythematous drugs market is Europe and is projected to reach nearly US$ 550
Mn and register a double digit CAGR due to higher prevalence of SLE in Europe. Among the
European countries Sweden, Iceland, Spain had the highest prevalence according to Lupus
Journal article, published in 2006. A drug called hydroxychloroquine being the last drug was
approved by FDA in 1955 for SLE treatment.